Alpha 2.0
Login Register
» Authors » G A Timony

G A Timony

Explore the profile of G A Timony including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 166
Followers 0
Related Specialties
Biochemistry
Oncology
Pharmacology
Top 10 Co-Authors
L B Angus
J B Stoudemire
K M Barone
P G Horgan
G R Larsen
T J Ahern
K S Henson
G E Morris
S Sharma
E Raymond
Published In
J Biol Chem
Anticancer Drugs
Radiat Res
Br J Pharmacol
Blood
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity
Scott F, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al.
Br J Pharmacol . 2016 Mar; 173(11):1778-92. PMID: 26990079
Background And Purpose: Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and endothelial barrier integrity. Stimulation of S1P1 receptors sequesters lymphocyte subsets in peripheral lymphoid organs, preventing...
2.
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units
Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, et al.
Anticancer Drugs . 1998 Jun; 9(4):327-31. PMID: 9635923
Bone morphogenetic protein-2 (BMP-2) is a differentiation factor for normal osteoblasts. BMP-2 is structurally related to transforming growth factor-beta which inhibits cell proliferation and enhances apoptosis. A recent study has...
3.
Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B
Brinkhous K, Sigman J, Read M, Stewart P, McCarthy K, Timony G, et al.
Blood . 1996 Oct; 88(7):2603-10. PMID: 8839853
Recombinant human factor IX (rFIX) has been expressed in transduced cultured cell systems since 1985. Because there has been limited in vivo testing of rFIX in hemophilia B subjects, this...
4.
Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
Larsen G, Timony G, Horgan P, Barone K, Henson K, Angus L, et al.
J Biol Chem . 1991 May; 266(13):8156-61. PMID: 1708773
Human tissue-type plasminogen activator (t-PA) is a glycoprotein used currently in thrombolytic therapy for patients with acute myocardial infarction. Due to its rapid rate of clearance from the circulation, continuous...
5.
Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous...
Ahern T, Angus L, Barone K, Brenner M, Horgan P, Morris G, et al.
J Biol Chem . 1991 Feb; 266(6):3715-23. PMID: 1847387
A novel triple-kringle plasminogen activator protein, PK1 delta FE1X, has been produced which is a genetic chimera between the fibrin binding kringle 1 domain of plasminogen and the two kringles...
6.
Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation
Ahern T, Morris G, Barone K, Horgan P, Timony G, Angus L, et al.
J Biol Chem . 1990 Apr; 265(10):5540-5. PMID: 2108143
Recombinant variants of tissue plasminogen activator (t-PA) containing either substitutions or deletions of amino acids within the fibronectin finger-like domain (residues 6-50) were found to exhibit widely varying in vivo...
7.
The disposition of ethiofos (WR-2721) in the isolated perfused rat liver
Coleman M, Fleckenstein L, Geary R, Brewer T, Timony G, Mangold D
Radiat Res . 1989 Feb; 117(2):334-41. PMID: 2537989
We have investigated the disposition of ethiofos (20 mg, 4 microCi [14C]ethiofos) in the isolated perfused rat liver preparation to determine the hepatic contribution to the poor oral bioavailability of...